DSM-5 criteria for Insomnia Disorder include a dissatisfaction with sleep quantity or quality associated with one or more of the following symptoms: difficulty initiating sleep, maintaining sleep, early morning awakening with inability to return to sleep. The sleep difficulty occurs at least three nights per week, is present for at least three months, and causes significant distress in one or various areas of functioning (American Psychiatric Association, 2013).
​
Insomnia affects your night and your day and is considered a 24-hour condition.
CBT-I is a non-pharmacological, brief, and effective treatment for insomnia that uses cognitive and behavioral interventions to address nocturnal and daytime insomnia symptoms.
CBT-I aims to target factors that may maintain insomnia over time, such as dysregulation of sleep drive, sleep-related anxiety, and sleep-interfering behaviors.
​
Treating insomnia with CBT-I -- as opposed to medication -- has several advantages, including fewer side effects and more durable effects following treatment discontinuation.
​
An average course of treatment lasts four to eight sessions.
​
A large body of research supports the efficacy of CBT-I. CBT-I is as effective as sedative-hypnotics during acute treatment (4–8 weeks) and is more effective than sedative-hypnotics in the long term (for example, more than 3 months after treatment).
​
The research shows that 70 to 80% of individuals who complete CBT-I improve their sleep, and 70% maintain gains after 2 years.
​
Self-pay sessions: Initial assessment is $180, and follow-up sessions are $160.
​
To use insurance, you must meet DSM-5-TR criteria for Insomnia Disorder at your assessment.
​
Florida and Texas:
​In-network with:
-
Aetna
-
Blue Cross Blue Shield of Massachusetts
-
Cigna and Cigna EAP
-
Lyra EAP
-
Optum (Oscar, Oxford Health Plans, UMR, United Healthcare, UHC Student Resources, AllSavers UHC, Harvard Pilgrim) and Optum Live & Work Well EAP
-
SpringHealth EAP
​
Vermont:
In-network with Lyra EAP and SpringHealth EAP only.